The trial realized the two its primary endpoints, with semaglutide two.four mg demonstrating statistically considerable and outstanding improvements in liver fibrosis without having worsening of steatohepatitis, and also resolution of steatohepatitis without any worsening of liver fibrosis in those with MASH compared to placebo.1Your Mounjaro pen w